Radiation 'Priming' tested to supercharge cancer immunotherapy
NCT ID NCT04454528
Summary
This study is testing if adding a single, targeted dose of radiation to an immunotherapy drug (pembrolizumab) before surgery is safe and can help shrink breast tumors. It involves about 27 patients with early-stage, operable breast cancer. Researchers want to see if this combination makes the immune system attack the cancer more effectively and leads to better outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.